Cardiff Oncology, Inc.

CRDF Nasdaq CIK: 0001213037

Company Information

Industry Biological Products, (No Diagnostic Substances)
SIC Code 2836
Entity Type operating
SEC Category Non-accelerated filerSmaller reporting company
State of Incorporation DE
Business Address 11055 FLINTKOTE AVENUE, SAN DIEGO, CA, 92121
Mailing Address 11055 FLINTKOTE AVENUE, SAN DIEGO, CA, 92121
Phone 858-952-7570
Fiscal Year End 1231
EIN 272004382

Financial Overview

FY2025

$16.50M
Total Liabilities
$82.95M
Stockholders' Equity
$51.47M
Cash & Equivalents

Recent SEC Filings

Form Type Date Filed Document
8-K Current report of material events April 2, 2026 View on SEC
4 Insider stock transaction report April 2, 2026 View on SEC
SCHEDULE 13G/A Passive ownership amendment March 26, 2026 View on SEC
8-K Current report of material events February 25, 2026 View on SEC
10-K Annual financial report February 24, 2026 View on SEC
8-K Current report of material events February 24, 2026 View on SEC
4 Insider stock transaction report February 18, 2026 View on SEC
4 Insider stock transaction report February 18, 2026 View on SEC
3 Initial insider ownership report February 9, 2026 View on SEC
8-K Current report of material events January 27, 2026 View on SEC

Material Events

8-K Leadership Change April 2, 2026
High Impact
  • Finalized leadership transition to CEO Mani Mohindru
  • Strategic pivot to optimize onvansertib clinical development
View Analysis

Related Companies

Companies in the same industry (SIC: 2836)

Investor Resources

Learn more about SEC filings and how to research public companies.

Important Disclaimer

This AI-generated analysis is for informational purposes only and does not constitute financial or investment advice. Always consult with qualified professionals and conduct your own research before making investment decisions.